4//SEC Filing
ACADIA PHARMACEUTICALS INC 4
Accession 0001415889-15-000615
$ACADCIK 0001070494operating
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 6:00 PM ET
Size
16.9 KB
Accession
0001415889-15-000615
Insider Transaction Report
Form 4
Rasmussen Torsten
Director
Transactions
- Exercise/Conversion
Common Stock
2015-02-17$8.49/sh+2,780$23,602→ 11,280 total(indirect: See footnote) - Exercise/Conversion
Common Stock
2015-02-17$8.49/sh+7,067$59,999→ 18,347 total(indirect: See footnote) - Exercise/Conversion
Common Stock
2015-02-17$1.36/sh+10,000$13,600→ 28,347 total(indirect: See footnote) - Sale
Common Stock
2015-02-17$35.05/sh−19,847$695,544→ 8,500 total(indirect: See footnote) - Exercise/Conversion
Stock option (right to buy)
2015-02-17−2,780→ 0 total(indirect: See footnote)Exercise: $8.49Exp: 2018-06-12→ Common Stock (2,780 underlying) - Exercise/Conversion
Stock option (right to buy)
2015-02-17−7,067→ 0 total(indirect: See footnote)Exercise: $8.49Exp: 2018-06-12→ Common Stock (7,067 underlying) - Exercise/Conversion
Stock option (right to buy)
2015-02-17−10,000→ 0 total(indirect: See footnote)Exercise: $1.36Exp: 2022-06-07→ Common Stock (10,000 underlying)
Footnotes (5)
- [F1]Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2014.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.10 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
- [F4]25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2008.
- [F5]25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 8, 2012.
Documents
Issuer
ACADIA PHARMACEUTICALS INC
CIK 0001070494
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001070494
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 6:00 PM ET
- Size
- 16.9 KB